Is a complete AARD research report available?

No complete published report is available for Aardvark Therapeutics, Inc. (AARD) on this page. Market-directory data, when present, is not a substitute for a reviewed stock analysis.

Aardvark Therapeutics, Inc. (AARD)

NASDAQ: AARD · USD

$6.40

+1.08 (+20.3%)· Recorded snapshot

Coverage state: Market snapshot only — no published research

Market snapshot recorded 2026-07-31 02:00 UTC. No published research is attached to this ticker. Prices and fundamentals on this server-rendered page are dated snapshots, not a real-time trading feed.

On-demand research

Generate the first AARD analysis

Start the full research workflow when this ticker is ready in our data system.

Market cap	139.6M
Net income (ttm)	-69.9M
EPS (ttm)	-$3.21
Shares out	21.8M
Volume	152,373
Price target	$14.5	+126.6%

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Net income (ttm): -69.9M
EPS (ttm): -$3.21
Market cap: 139.6M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
ALNY	Alnylam Pharmaceuticals, Inc.	27.4B	36.9x	5.7x	96.6%	+47.5%	-37.8%	Strong Buy
ARGX	argenx SE	53.8B	31.3x	10.1x	50.6%	+58.8%	+45.7%	Strong Buy
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Hold

All AARD indicators

Market & fundamental data

Available fields

172

Groups with data

Currency

USD

Showing 172 of 172 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001774857
Company name	Aardvark Therapeutics, Inc.
Country	United States
Country code	US
Cusip	002942100
Employees	40
Employees Change	18%
Employees Change Percent	81.82
Enterprise value	$48.8M
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
IPO Date	2025-02-13
Isin	US0029421007
Last refreshed	2026-07-31
Market cap	$139.6M
Market cap category	Micro-Cap
Price	$6.4
Price currency	USD
Sector	Healthcare
Sector PE	45.21
Sector PE Fwd	23.64
Sic	2834
Symbol	AARD
Website	https://aardvarktherapeutics.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-50.04%
FCF yield	-44.22%
P/B ratio	1.61x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Net Income	$-69.9M
Net Income Growth Years	0%
Profit Per Employee	$-1.7M
ROA	-36.54
ROCE	-85.9
ROE	-58.79
ROIC	-39.12

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	-50.72%
EPS Growth Years	1
Revenue Growth Years	0x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Assets	$98.6M
Cash	$91.2M
Current Assets	$93.6M
Current Liabilities	$11.6M
Debt	$336,000
Debt Equity	$0
Equity	$87M
Liabilities	$11.6M
Long Term Assets	$5M
Long Term Liabilities	$0
Net Cash	$90.9M
Net Cash By Market Cap	$65.08
Net Cash Growth	-39.64%
Net Debt Equity	$-1.04
Tangible Book Value	$87M
Tangible Book Value Per Share	$3.99

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	8.06
Net Working Capital	$-8.9M
Quick ratio	7.86
Working Capital	$82M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-245.54%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	-50.69%
200-day SMA	8.59
50-day SMA	4.97
50-day SMA vs 200-day SMA	50under200
All Time High	19.58
All Time High Change	-67.31%
All Time High Date	2025-02-20
All Time Low	3.35
All Time Low Change	91.04%
All Time Low Date	2026-03-27
ATR	0.77
Beta1y	3.76
Beta2y	2.33
Ch YTD	-51.24
High	6.44
High52	17.94
High52 Date	2025-10-08
High52ch	-64.33%
Low	5.42
Low52	3.35
Low52 Date	2026-03-27
Low52ch	91.05%
Ma50ch	28.77%
Price vs 200-day SMA	-25.47%
RSI	54.79
RSI Monthly	45.57
RSI Weekly	47.2
Sharpe ratio	0.1x
Sortino ratio	0.18
Total Return	-245.54%
Tr YTD	-51.24
Tr1m	23.55%
Tr1w	0.16%
Tr3m	22.84%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	12
Analyst Count Top	7
Analyst Price Target Top	$16.4
Analyst Ratings	Buy
Analyst Ratings Top	Buy
Earnings EPS Estimate	$-0.87
Operating Income	$-74.7M
Price target	$14.5
Price Target Change	$127
Price Target Change Top	$156

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	10,910,298%
Float Percent	50.01%
Shares Insiders	16.33%
Shares Institutions	23.24%
Shares Out	21,816,385
Shares Qo Q	0.15%
Shares Yo Y	245.54%
Short Float	5.97%
Short Ratio	1.34
Short Shares	2.99

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-67.5M
Adjusted OCF	-67,372,000
Average Volume	376,949x
Bv Per Share	3.99
CAPEX	$-95,000
Ch1m	23.55
Ch1w	0.16
Ch1y	-50.69
Ch3m	22.84
Ch6m	-52.06
Change	20.3%
Change From Open	17.22
Close	5.32
Days Gap	2.63
Depreciation Amortization	42,000
Dollar Volume	975,187.2
Earnings Date	2026-08-07
Earnings Time	amc
EBIT	$-74.7M
EBITDA	$-74.7M
EPS	$-3.21
F Score	1
FCF	$-61.7M
FCF EV Yield	-126.63x
FCF Per Share	$-2.83
Financing CF	378,000
Fiscal Year End	December
Founded	2,017
Investing CF	97,207,000
Ipr	-60
Iprfo	-57.84
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-05-07
Last Report Date	2026-03-31
Last Split Type	Never
Last10k Filing Date	2026-03-23
Ma150	7.54
Ma150ch	-15.14%
Ma20	6.09
Ma20ch	5.16%
Net CF	35,932,000
Next Earnings Date	2026-08-12
Open	5.46
Optionable	Yes
Position In Range	96.08
Post Close	6.4
Postmarket Change Percent	1.88
Postmarket Price	$6.52
Ppne	269,000
Price Date	2026-07-30
Ptbv Ratio	1.61
Relative Volume	0.4x
Share Based Comp	5,719,000
Tr6m	-52.06%
Us State	California
Volume	152,373

Aardvark Therapeutics, Inc. (AARD)

Coverage state: Market snapshot only — no published research

Generate the first AARD analysis

Price

Financial snapshot

Fair-value bridge

Analyst consensus

Latest news · AARD

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All AARD indicators

Profile and market data

Valuation

Profitability

Growth

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Analyst estimates

Ownership and float

Other indicators

Deeper analysis on AARD

Frequently asked questions